204 related articles for article (PubMed ID: 28947947)
1. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.
Hoegenauer K; Soldermann N; Zécri F; Strang RS; Graveleau N; Wolf RM; Cooke NG; Smith AB; Hollingworth GJ; Blanz J; Gutmann S; Rummel G; Littlewood-Evans A; Burkhart C
ACS Med Chem Lett; 2017 Sep; 8(9):975-980. PubMed ID: 28947947
[TBL] [Abstract][Full Text] [Related]
2. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
[TBL] [Abstract][Full Text] [Related]
3. PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond.
Cant AJ; Chandra A; Munro E; Rao VK; Lucas CL
J Allergy Clin Immunol Pract; 2024 Jan; 12(1):69-78. PubMed ID: 37777067
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.
Hoegenauer K; Soldermann N; Stauffer F; Furet P; Graveleau N; Smith AB; Hebach C; Hollingworth GJ; Lewis I; Gutmann S; Rummel G; Knapp M; Wolf RM; Blanz J; Feifel R; Burkhart C; Zécri F
ACS Med Chem Lett; 2016 Aug; 7(8):762-7. PubMed ID: 27563400
[TBL] [Abstract][Full Text] [Related]
5. Interim analysis: Open-label extension study of leniolisib for patients with APDS.
Rao VK; Kulm E; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Dalm VA; Trizzino A; Zharankova Y; Webster S; Orpia A; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Relan A; Holland SM; Lenardo MJ; Uzel G
J Allergy Clin Immunol; 2024 Jan; 153(1):265-274.e9. PubMed ID: 37797893
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties.
Hoegenauer K; Soldermann N; Hebach C; Hollingworth GJ; Lewis I; von Matt A; Smith AB; Wolf RM; Wilcken R; Haasen D; Burkhart C; Zécri F
Bioorg Med Chem Lett; 2016 Dec; 26(23):5657-5662. PubMed ID: 27816514
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases.
Erra M; Taltavull J; Gréco A; Bernal FJ; Caturla JF; Gràcia J; Domínguez M; Sabaté M; Paris S; Soria S; Hernández B; Armengol C; Cabedo J; Bravo M; Calama E; Miralpeix M; Lehner MD
ACS Med Chem Lett; 2017 Jan; 8(1):118-123. PubMed ID: 28105286
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidyl Inositol 3-Kinase (PI3K)-Inhibitor CDZ173 protects against LPS-induced osteolysis.
Wu Z; Li X; Chen X; He X; Chen Y; Zhang L; Li Z; Yang M; Yuan G; Shi B; Chen N; Li N; Feng H; Zhou M; Rui G; Xu F; Xu R
Front Pharmacol; 2022; 13():1021714. PubMed ID: 36686650
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Development of Pyrazolo[1,5-
Stypik M; Michałek S; Orłowska N; Zagozda M; Dziachan M; Banach M; Turowski P; Gunerka P; Zdżalik-Bielecka D; Stańczak A; Kędzierska U; Mulewski K; Smuga D; Maruszak W; Gurba-Bryśkiewicz L; Leniak A; Pietruś W; Ochal Z; Mach M; Zygmunt B; Pieczykolan J; Dubiel K; Wieczorek M
Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015075
[TBL] [Abstract][Full Text] [Related]
11. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
12.
Pearson D; Garnier M; Luneau A; James AD; Walles M
Xenobiotica; 2019 Aug; 49(8):953-960. PubMed ID: 30215545
[TBL] [Abstract][Full Text] [Related]
13. INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ).
Yue EW; Li YL; Douty B; He C; Mei S; Wayland B; Maduskuie T; Falahatpisheh N; Sparks RB; Polam P; Zhu W; Glenn J; Feng H; Zhang K; Li Y; He X; Katiyar K; Covington M; Feldman P; Shin N; Wang KH; Diamond S; Li Y; Koblish HK; Hall L; Scherle P; Yeleswaram S; Xue CB; Metcalf B; Combs AP; Yao W
ACS Med Chem Lett; 2019 Nov; 10(11):1554-1560. PubMed ID: 31749910
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome.
Rao VK; Kulm E; Grossman J; Buchbinder D; Chong H; Bradt J; Webster S; Šedivá A; Dalm VA; Uzel G
Blood Adv; 2024 Jun; 8(12):3092-3108. PubMed ID: 38593221
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.
Rao VK; Webster S; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Conlon N; Coulter T; Dalm VA; Trizzino A; Zharankova Y; Kulm E; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Kucher K; Relan A; Holland SM; Lenardo MJ; Uzel G
Blood; 2023 Mar; 141(9):971-983. PubMed ID: 36399712
[TBL] [Abstract][Full Text] [Related]
16. Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor.
Cai Y; Yu J; Ren P; He J; Wu Z; Xiao K; Jia H; Wang J; Sai Y; Dai G; Li X; Su W; Ngo K; Castro G; Acton PD; Fung-Leung WP; Edwards JP; Venable J; Rao TS
Pharmacol Res Perspect; 2020 Feb; 8(1):e00559. PubMed ID: 31956418
[TBL] [Abstract][Full Text] [Related]
17. INCB040093 Is a Novel PI3K
Shin N; Li YL; Mei S; Wang KH; Hall L; Katiyar K; Wang Q; Yang G; Rumberger B; Leffet L; He X; Rupar M; Bowman K; Favata M; Li J; Liu M; Li Y; Covington M; Koblish H; Soloviev M; Shuey D; Burn T; Diamond S; Fridman J; Combs A; Yao W; Yeleswaram S; Hollis G; Vaddi K; Huber R; Newton R; Scherle P
J Pharmacol Exp Ther; 2018 Jan; 364(1):120-130. PubMed ID: 29127109
[TBL] [Abstract][Full Text] [Related]
18. Leniolisib: First Approval.
Duggan S; Al-Salama ZT
Drugs; 2023 Jul; 83(10):943-948. PubMed ID: 37256490
[TBL] [Abstract][Full Text] [Related]
19. From PIM1 to PI3Kδ via GSK3β: Target Hopping through the Kinome.
Henley ZA; Bax BD; Inglesby LM; Champigny A; Gaines S; Faulder P; Le J; Thomas DA; Washio Y; Baldwin IR
ACS Med Chem Lett; 2017 Oct; 8(10):1093-1098. PubMed ID: 29057057
[TBL] [Abstract][Full Text] [Related]
20. Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitor.
Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Suzuki D; Moritomo A; Kubo S; Nakamura K; Yamagami K; Yokoo K; Fukahori H
Bioorg Med Chem; 2019 Mar; 27(6):1056-1064. PubMed ID: 30755348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
